Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 1324Neoplasms 982Carcinoma, Non-Small-Cell Lung 860Prostatic Neoplasms 724Colorectal Neoplasms 666Lung Neoplasms 551Leukemia, Myeloid, Acute 475Neoplasm Metastasis 434Pancreatic Neoplasms 419Carcinoma, Hepatocellular 407Multiple Myeloma 396Ovarian Neoplasms 392Stomach Neoplasms 379Recurrence 364Squamous Cell Carcinoma of Head and Neck 325Melanoma 294Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Glioblastoma 264Head and Neck Neoplasms 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 234Lymphoma 228Rectal Neoplasms 222Esophageal Neoplasms 222Sarcoma 213Carcinoma, Renal Cell 203Colonic Neoplasms 194Lymphoma, Non-Hodgkin 191

Interventions

tislelizumab 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × Cervical Cancer Recurrent × Clear all
NCT06455046 2024-06-12

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Cervical Cancer Recurrent

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Gynecologic

Cervical Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡